^
Association details:
Biomarker:BRAF G469V
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy

Published date:
08/08/2023
Excerpt:
In NADIM trials, pathogenic or likely pathogenic genetic alterations in the BRAF gene occurred in 4.35% of the patients (n=4; p.L597Q, p.G469V, p.G464, p.V600E). BRAF pathogenic mutations were significantly enriched in tumors showing pathological complete response after neoadjuvant treatment with chemo-immunotherapy.
Secondary therapy:
Chemotherapy